Navigating the Tightrope of Transfusions, Chelation, and Joint Health in Thalassemic Individuals: High Time to Find Answers!
Arihant Jain
Citation Information :
Jain A. Navigating the Tightrope of Transfusions, Chelation, and Joint Health in Thalassemic Individuals: High Time to Find Answers!. J Postgrad Med Edu Res 2024; 58 (3):105-106.
Farmakis D, Giakoumis A, Angastiniotis M, et al. The changing epidemiology of the ageing thalassaemia populations: a position statement of the Thalassaemia International Federation. Eur J Haematol 2020;105(1):16–23. DOI: 10.1111/ejh.13410
Basanagoudar PL, Sharma S, Aggarwal S, et al. Prevalence of thalassemic arthropathy in transfusion dependent β-thalassemia patients: an observational study. J Postgrad Med Educ Res 2024;58(2):58–59. DOI: 10.5005/jp-journals-10028-1658
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020;26(S6):1–158. DOI: 10.1111/hae.14046
Farmakis D, Porter J, Taher A, et al. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere 2022;6(8):e732. DOI: 10.1097/HS9.0000000000000732
Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312. DOI: 10.1046/j.1365-2141.2000.01866.x
Sharma R, Anand R, Chandra J, et al. Distal ulnar changes in children with thalassemia and deferiprone related arthropathy. Pediatr blood cancer. 2013;60(12):1957–1962. DOI: 10.1002/pbc.24678
Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82(2):460–466. DOI: 10.1111/j.1365-2141.1992.tb06445.x
